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Dear Editor, 
  
Pyae Phyo and colleagues [1] conclude that the increasing prevalence of K13 mutations is the decisive factor 
for the declining efficacy of mefloquine-artesunate (MAS3) reported on the Thai-Myanmar border. They then 
make an unsupported assertion that the definition of “artemisinin resistance” by ourselves [2] may have 
contributed to a failure to contain artemisinin-based treatment failures in the greater Mekong area. This has 
put us firmly in the distinguished company of 2 other independent groups who also critically assessed the term 
‘artemisinin resistance’ and with whom we shared similar conclusions [2-4].  
  
After all, it was our collaborative efforts that first established the molecular marker of increased pfmdr1 copy 
number as being associated with treatment failures of artemisinin combination therapies (TFACT) [5]. Others 
confirmed our findings in different geographic areas (e.g. [6]). Some of our coauthors [5] at the time asserted 
without compunction that ‘artemisinin resistance’ would be unlikely to emerge in their lifetimes. They have 
not been accused of aiding the spread of parasites manifesting TFACT. 
  
How have some later ideas in our opinion piece on ‘anti-dogmatic approaches to artemisinin resistance’ stood 
the test of time? We suggested that ‘increased gametocyte production’ may become ‘a marker of slow 
parasite clearance phenotype’ [2] and were gratified to see that some authors on Pyae Phyo’s paper went on 
to observe that ‘The higher proportions of pre-treatment and post-treatment gametocytemia in patients with 
slow parasite clearance suggest that artemisinin-resistance P. falciparum infections have a transmission 
advantage…’ [7] despite our opinion being unreferenced.  
  
We also suggested that because conventional ACTs use incomplete courses of artemisinins ‘Contending that 
there is artemisinin resistance when cure of patients relies on the partner drug of an artemisinin is difficult to 
substantiate without additional studies’ [2]. Once again, our suggestions have been borne out by the 
important finding that kelch13 C508Y in Cambodia is associated with increased IC50 values to piperaquine in 
DHA-piperaquine treatments – focusing attention on the partner in the ACT and not only the artemisinin 
component [8]. The use of longer courses of ACT further supported our suggestion that artemisinins are 
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conventionally underdosed [9], including findings made by the same individuals [7] who now criticise the very 
publication in which that suggestion was made. 
  
Defining the precise nature of a problem such as multidrug resistant malaria provides the greatest service to 
those trying to deal with it. Critically examining terms such as ‘artemisinin resistance’ cannot stifle thinking 
about multidrug resistant parasites. In contrast, as we have illustrated it stimulates studies on resistant 
phenotypes rather than stimulating their geographic spread, particularly in light of the dispersed global 
distribution of kelch mutations [10]. 
  
To manage the problem of multidrug resistance we need new antimalarial classes and new diagnostics that 
can tell us about drug resistance status as well as confirming infection with malaria parasites. But to underpin 
these advances, we need to understand better both the mechanisms of action of artemisinins and how 
resistance to this class develops. These advances need inclusive debates rather than exclusive crusades.  
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